Clinical Trial Update: A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing PF-06439535 plus paclitaxel and carboplatin against bevacizumab plus paclitaxel and carboplatin in advanced non-squamous non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• PF-06439535

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-06-27